Vacuna meningococo W135 y efectos 2ios

La vacuna tetravalente Menactra que se está utilizando en Chile debido al brote de meningitis por meningococo del grupo W135 no está comercializada en Europa, donde disponemos de otra, llamada Menveo, contra los mismos gérmenes pero solo autorizada para su administración a personas a partir de los 2 años de edad.

Le podemos refemitr a la información aprobada por la  Food and Drug Administration (FDA) de EE. UU. y contenida en el prospecto de este producto en aquel país, donde consta lo siguiente:

----------------------------INDICATIONS AND USAGE----------------------
Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by N meningitidis serogroups A, C, Y and W-135. Menactra is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.
----------------------DOSAGE AND ADMINISTRATION-------------------
A 0.5 mL dose for intramuscular injection.
- Children 9 through 23 months of age: Two doses, three months apart.
- Individuals 2 through 55 years of age: A single dose.
---------------------DOSAGE FORMS AND STRENGTHS-----------------
Liquid solution supplied in 0.5 mL single-dose vials
-------------------------------CONTRAINDICATIONS------------------------
- Severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197containing vaccine, or to any component of Menactra vaccine.
-----------------------WARNINGS AND PRECAUTIONS-----------------
- Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. The decision to give Menactra vaccine should take into account the potential benefits and risks.
------------------------------ADVERSE REACTIONS-------------------------
- Common (≥10%) solicited adverse events in infants and toddlers 9 and 12 months of age were injection site tenderness, erythema, and swelling; irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever.
- Common (≥10%) solicited adverse events in individuals 2 through 55 years of age were injection site pain, redness, induration, and swelling; anorexia and diarrhea. Other common solicited adverse events were irritability and drowsiness (2-10 years of age), headache, fatigue, malaise, and arthralgia (11-55 years of age).

Comité Asesor de Vacunas de la Asociación Española de Pediatría